Haoxi Health Technology Limited Class A (HAO) AI Stock Analysis

• Market Cap: $22.28M
• Dividend Yield: N/A
• Average Volume (3M): 970.53K
• Price to Earnings (P/E): 3.4
• Beta (1Y): 1.33
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 30
• Sector: Communication Services
• Sector Strength: 97
• Industry: Advertising Agencies
• EPS (TTM): 0.01
• Shares Outstanding: 2,131,595
• 10 Day Avg. Volume: 34,415
• 30 Day Avg. Volume: 970,526
• PEG Ratio: 1.10
• Price to Book (P/B): 139.26
• Price to Sales (P/S): 32.35
• P/FCF Ratio: -1.96K
• Enterprise Value/Market Cap: 7.48
• Enterprise Value/Revenue: 3.40
• Enterprise Value/Gross Profit: 82.13
• Enterprise Value/Ebitda: 171.62
• 1Y Price Target: $1.50
• Price Target Upside: 31.58% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 68 Neutral
• Price Target: $1.50 ▲(31.58% Upside)

The overall score reflects a combination of strong valuation, with the stock appearing undervalued, and moderate financial performance, highlighted by revenue growth but hampered by cash flow issues. Technical analysis indicates a lack of strong momentum, contributing to the overall risk profile.

Haoxi Health Technology Limited Class A Business Overview & Revenue Model

Company Description

Haoxi Health Technology Limited Class A (HAO) is a pioneering health technology company focused on developing innovative solutions aimed at improving health outcomes through advanced medical technologies. Operating primarily in the healthcare sector, HAO specializes in the design and manufacturing of medical devices, health monitoring systems, and telemedicine solutions. The company leverages cutting-edge technology to create products that enhance patient care, streamline healthcare delivery, and facilitate remote health monitoring.

How the Company Makes Money

Haoxi Health Technology generates revenue through multiple streams, including the sale of medical devices and health monitoring systems directly to healthcare providers and institutions. Additionally, the company offers subscription-based services for its telemedicine platforms, which allow patients to consult with healthcare professionals remotely. Partnerships with hospitals and clinics play a significant role in driving sales and expanding market reach. Furthermore, HAO may benefit from government contracts and grants aimed at advancing health technology solutions, contributing to its overall earnings.

Haoxi Health Technology Limited Class A Financial Statement Overview

Summary

Haoxi Health Technology Limited Class A shows promising growth in revenue and profitability, with improved margins and a stronger balance sheet. However, cash flow challenges persist, highlighting the need for improved cash management. The company is on a positive trajectory but must address cash flow issues to ensure long-term sustainability.

Income Statement

The company has shown strong revenue growth, with a significant increase from $28.2M in 2023 to $48.5M in 2024. Gross profit margin improved slightly, indicating better cost management. Net profit margin also improved, reflecting enhanced profitability. However, the EBIT and EBITDA margins indicate room for further operational efficiency improvements.

Balance Sheet

The company's debt-to-equity ratio is low, suggesting conservative leverage. The return on equity is positive, reflecting profitability, but the equity ratio indicates a reliance on liabilities. The significant increase in stockholders' equity is a positive sign, but past negative equity raises concerns about historical financial stability.

Cash Flow

Operating cash flow remains negative, which is a concern for sustainability. However, the company has improved its free cash flow position compared to previous years. The free cash flow to net income ratio indicates challenges in converting profits into cash, suggesting a need for better cash management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	48.52M	28.23M	16.16M	12.85M
Gross Profit	2.75M	2.06M	648.72K	605.58K
EBITDA	1.79M	1.22M	271.77K	330.96K
Net Income	1.29M	969.75K	244.59K	304.06K
Balance Sheet
Total Assets	15.51M	4.46M	542.99K	2.81M
Cash, Cash Equivalents and Short-Term Investments	6.66M	1.20M	293.51K	55.89K
Total Debt	1.20M	850.06K	505.40K	335.03K
Total Liabilities	4.23M	2.90M	2.01M	4.74M
Stockholders Equity	11.27M	1.57M	-1.47M	-1.93M
Cash Flow
Free Cash Flow	-802.94K	-917.63K	-684.06K	2.65M
Operating Cash Flow	-747.58K	-872.13K	-675.36K	2.65M
Investing Cash Flow	-3.13M	-45.50K	-8.70K	-3.26K
Financing Cash Flow	9.32M	1.80M	933.22K	-2.61M

Haoxi Health Technology Limited Class A Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAO, the sentiment is Negative. The current price of 1.14 is below the 20-day moving average (MA) of 1.23, below the 50-day MA of 1.22, and below the 200-day MA of 1.61, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 42.01 is Neutral, neither overbought nor oversold. The STOCH value of 14.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HAO.

Haoxi Health Technology Limited Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HAO	68 Neutral	$22.28M	3.44	2.92%	―	―	―
Sector *	60 Neutral	$48.67B	4.58	-11.27%	4.14%	2.83%	-41.78%
WIMI	56 Neutral	$79.78M	3.57	15.20%	―	-27.98%	―
MCHX	48 Neutral	$80.41M	―	-13.93%	―	-2.64%	6.48%
INUV	45 Neutral	$45.69M	―	-36.41%	―	21.45%	41.21%
FLNT	44 Neutral	$62.12M	―	-115.36%	―	-12.84%	63.95%
DRCT	44 Neutral	$7.74M	―	-320.07%	―	-74.79%	-690.57%